Abstract Phosphorylation of cardiac troponin is a key mechanism involved in regulation of contractile function. In vitro kinase assays revealed that lysates prepared from resting cardiomyocytes contain cardiac troponin I (cTnI) and cTnT kinase activity. cTnI phosphorylation is inhibited by pharmacologic inhibitors of PKA, PKC, Rho kinase and PKC effectors such as RSK and PKD; these kinase inhibitors do not inhibit phosphorylation of cTnT. Rather, cTnT phosphorylation is decreased by the Raf inhibitor GW5074. In vitro kinase assays show that recombinant Raf phosphorylates cTnT, and that Raf-dependent cTnT phosphorylation is abrogated by a T206E substitution; Raf does not phosphorylate cTnI. These studies identify Raf-dependent cTnT-Thr 206 phosphorylation as a novel mechanism that would link growth factor-dependent signaling pathways to dynamic changes in cardiac contractile function.
Introduction
Myofilament contraction and relaxation is regulated, in a Ca 2? -dependent manner, by the cooperative interaction of cardiac troponin (cTn) with tropomyosin (Tm). The troponin complex is comprised of three distinct proteins with specific functions. Troponin C (TnC) binds Ca 2? , troponin I (TnI) inhibits the myosin-actin cross-bridge formation, and troponin T (TnT) binds Tm and tethers the cTn complex to the thin filament. TnT functions as a lever to transmit signals generated by Ca 2? -dependent conformational changes in TnC-TnI to Tm, regulating actin-myosin interactions . The functional importance of the cTn complex is underlined by the numerous charge mutations in these proteins that lead to familial hypertrophic cardiomyopathies (Morimoto 2008) . Charged residues or phosphorylations control the intermolecular interactions between these sarcomeric proteins and regulate cardiac contractile function.
The focus of much of the literature has been on cardiac TnI, which is phosphorylated by several serine/threonine kinases (PKA, PKC, PKD, ROCK), leading to important changes in contractile function (Haworth et al. 2004; Layland et al. 2005; Vahebi et al. 2005 ). While TnT is not phosphorylated by PKA, its phosphorylation by PKC (at Thr 197 , Ser 201 , Thr 206 , and Thr 287 sites in the functionally important C-terminal half of the protein that interacts with TnI, TnC, and possibly Tm) has been linked to impaired myofilament function (Sumandea et al. 2003) . TnT phosphorylation by ASK1 (a stress-activated kinase that has been implicated specifically in TNF and oxidant stress responses) also has been associated with a decrease in cardiomyocyte contractility (He et al. 2003) . The functional importance of TnT phosphorylation has been exposed in transgenic models where replacement of cardiac TnT with skeletal TnT (that lacks regulatory phosphorylation sites) blunts PKC-dependent depression of cardiac contraction (Montgomery et al. 2001) . Mutagenesis studies (with PKC phosphorylation sites substituted by either alanine or phosphomimetic glutamate residues) implicate Thr 206 as a functionally important phosphorylation site (Sumandea et al. 2003) .
In the course of recent studies that examined the role of PKCd as a TnI kinase (Sumandea et al. 2008 ), we identified a TnT kinase activity that could not be attributed to PKC in cardiomyocytes lysates. Studies reported herein identify Raf as a novel cardiomyocyte TnT kinase.
Materials and methods

Materials
Recombinant PKCd was from Calbiochem. Recombinant MEK, PKA, PKCa, PKCbII, PKCe and PKD1 were from Upstate. Recombinant truncated/activated Raf-1 (amino acids 306-648 in the catalytic domain, with Y340D/Y341D substitutions) and full-length Pak-1 were obtained from Invitrogen. Other chemicals were reagent grade.
Cardiomyocyte culture
Cardiomyocytes were isolated from hearts of 2-day-old Wistar rats by a trypsin dispersion procedure that uses a differential attachment procedure followed by irradiation to enrich for cardiomyocytes. Cells were plated on protamine sulfate-coated culture dishes at a density of 5 9 10 6 cells/ 100 mm dish and grown in MEM (Gibco, BRL) supplemented with 10% fetal calf serum for 4 days. Cells were lysed in homogenization buffer (20 mM Tris-Cl, pH 7.5, 2 mM EDTA, 2 mM EGTA, 0.5 mM DTT, 0.2% Triton X-100, 50 lg/ml aprotinin, 50 lg/ml leupeptin, 50 lg/ml benzamidine, 1 mM PMSF, 5 lM pepstatin A, 1 mM sodium orthovanadate, 100 mM sodium fluoride, 10 mM sodium pyrophosphate, 0.1 lM calyculin). Cell extracts were used for in vitro kinase assays.
Troponin expression and purification
Recombinant heterotrimeric troponin complexes were prepared according to very stringent conditions designed to avoid the presence of any contaminants, as previously described (Sumandea et al. 2003) . Briefly, each subunit (cardiac TnT-WT and -T206E, TnI and TnC) was expressed independently in E. coli, denatured in a 6 M urea solution and purified to [90% using a combination of ammonium sulfate fractionation, anionic and cationic exchange chromatography (on an AKTA-FPLC system), and extensive dialysis. Recombinant heterotrimeric cTn complexes were reconstituted by mixing equimolar amounts of cTnT (either wt or T206E), cTnI and cTnC in a solubilization buffer containing 6 M Urea, 50 mM Tris pH 8.0, 1 M NaCl, 5 mM MgCl 2 , 1 mM CaCl 2 , 1 mM DTT. The solution was subjected to sequential dialysis using 0.7 M NaCl, 0.4 M NaCl, and finally 0.05 M NaCl in the above buffer minus urea. cTn complex was then further purified from any contaminants on a high performance Resource Q column (GE Healthcare). Troponin complex elutes as a sharp peak well separated from any unincorporated monomeric TnI or TnC subunits. Troponin complexes were tested using in vitro reconstituted myofilament assays for their ability to regulate myosin ATPase activity in a [Ca 2? ] dependent manner.
In vitro kinase assays with cell extracts
In vitro kinase assays were performed with 11 lg of cardiomyocyte extract. Assays were performed in 110 ll of a reaction buffer containing 20 mM Tris-Cl, pH 7.5, 3 mM MgCl 2 , 0.7 mM EDTA, 0.7 mM EGTA, 0.24 mM DTT, 0.9 mM sodium vanadate, 120 mM NaCl, 0.073% Triton X-100, 0.36 mM phenylmethylsulfonyl fluoride, 0.36 mM sodium orthovanadate, 36 mM sodium fluoride, 3.6 mM sodium pyrophosphate, 0.06 lM calyculin, 15 lg of recombinant cardiac troponin complex (cTn), and [c-32 P]ATP (2 lCi, 66 lM). Incubations were for 16 min at 30°C.
In vitro kinase assays with recombinant PKCs, PKD1 and PKA In vitro kinase assays were performed in 110 ll of a reaction buffer containing 38 mM Tris-Cl, pH 7.5, 6 mM MgCl 2 , 0.6 mM EDTA, 0.6 mM EGTA, 1.6 mM DTT, 136 mM NaCl, 4.2% glycerol, 83 lg/ml phosphatidylserine, 160 nM PMA, 4 lg of cTn, and [c-32 P]ATP (2 lCi, 66 lM). Incubations were for 16 min at 30°C in the presence of PKCd (0.032 units), PKCa (0.063 units), PKCbII (0.063 units), PKCe (0.184 units), PKD1 (0.026 units), or PKA (3.84 units).
In vitro kinase assays with recombinant c-Raf-1 and Pak
In vitro kinase assays were performed in 40 ll of a reaction buffer containing 30 mM HEPES, pH 7.4, 10 mM MgCl 2 , 5 mM EGTA, 1 mM DTT, 115 mM NaCl, 1 mM sodium orthovanadate, 25 mM b-glycerophosphate, 7.5 lg of cTn, and [c-32 P]ATP (15 lCi, 15 lM). Incubations were for 30 min at 25°C in the absence or presence of c-Raf-1 (15 ng) or Pak (20 ng).
Results
In vitro kinase assays were performed with lysates from resting cardiomyocytes in buffers containing [ 32 P]ATP and cTn complex as substrate (containing equimolar concentrations of cTnT, cTnC, and cTnI). These studies show that both cTnI and cTnT kinase activities are recovered in cardiomyocyte lysates (Fig. 1a, b) . cTnI phosphorylation is effectively blocked by H7 (a relatively non-specific serine/ threonine kinase inhibitor), GF109203X (which inhibits PKC isoforms and RSK), H89 (a PKA inhibitor), and UCN-01. UCN-01 is a 7-hydroxystaurosporine derivative that is relatively selective for PDK-1 and checkpoint kinases at low concentrations, but inhibits PKC isoforms at the concentrations used in this study (Guo et al. 2006; Komander et al. 2003) . Cardiomyocytes co-express multiple PKC isoforms, including conventional PKCs (cPKCs) such as PKCa and arguably PKCb and novel PKCs (nPKCs) such as PKCd and PKCe. While the general consensus is that cPKCs are five to eightfold more abundant than nPKC in most cardiomyocyte preparations (Komander et al. 2003) , cTnI phosphorylation is attenuated (but not completely inhibited) by Gö6976, which selectively inhibits cPKC isoforms (and not nPKCs) and also blocks the catalytic activity of PKD [a different enzyme that also has been implicated as a cTnI kinase (Haworth et al. 2004) ]. cTnI phosphorylation also is attenuated by Y27632, a Rho kinase (ROCK) inhibitor. Ponceau staining of membranes show that cTnI appear as either a single band or as a doublet in different preparations of the troponin complex. This represents an unfortunate technical feature of this set of experiments; it is presumed to reflect some cTnI degradation during the assays (and has no biological significance). The different cTnI mobilities do not result from differences in phosphorylation pattern.
These results are consistent with recent studies implicating PKA, PKCs, PKD, RSK, and ROCK as cTnI kinases (Haworth et al. 2004; Itoh et al. 2005; Noland et al. 1996; Vahebi et al. 2005) . Of note, none of these kinase inhibitors blocked cTnT phosphorylation. While this is consistent with the additional observation that recombinant PKCe, PKD and PKA phosphorylate cTnI but they do not act as cTnT kinases, it is at odds with results of kinase assays with PKCa (an abundant enzyme in cardiomyocyte lysates; Fig. 1 Cardiac lysates contain cTnT kinase activity that is blocked by GW5074 (a Raf inhibitor) and not by inhibitors of various other serine/threonine kinases. Lysates from resting cardiomyocytes were subjected to in vitro kinase assays without (lane 1) and with troponin complex (lanes 2-11) . The following kinase inhibitors were used in the assays: 50 lM H7, 5 lM GF109203X, 5 lM Go6976, 20 lM H89, 5 lM U0126, 10 lM GW5074, 10 nM Rapamycin, 10 lM Y27632, and 10 lM UCN-01. It is worth noting that UCN-01 specifically blocks PDK-1 and checkpoint kinases at low concentrations, but UCN-01 also inhibits PKC isoforms at the concentrations used in these studies. Autoradiogram and Ponceau staining are depicted in the left panels, with a quantification of the data in the right panel. These results were replicated in two similar experiments. Similar results also were obtained in experiments that used lysates from H 2 O 2 -treated cardiomyocytes cultures J Muscle Res Cell Motil (2009) 30:67-72 69 Rohde et al. 2000) and other PKC isoforms (such as PKCd and PKCbII) that act as dual in vitro cTnI/cTnT kinases (Fig. 2 ). An explanation for the failure to detect GF109203X-sensitive cTnT kinase activity (attributable to PKCa) in cardiomyocytes lysates is not obvious and will require further analysis. Nevertheless, Fig. 1 shows that cTnT phosphorylation is effectively blocked by GW5074, an inhibitor of Raf and PIM kinases, that also exerts a lesser inhibitory effect on RIP2, HIPK2, and MST2 (Bain et al. 2007 ). GW5074 does not block cTnI kinase activity. These results suggest that a GW5074-sensitive kinase is the predominant cTnT kinase recovered in cardiomyocyte lysates. Of note, studies performed in parallel with lysates from H 2 O 2 -treated cardiomyocytes provided qualitatively identical results, indicating that oxidative stress does not result in the activation of additional/alternative cardiomyocyte troponin kinases (data not shown). We used in vitro kinase assays to directly explore the potential role of Raf as a cTnT kinase. Initial studies used MEK as a conventional Raf substrate. These studies show that: (1) Raf phosphorylates the conventional Raf substrate MEK (Fig. 3a) (2) Raf undergoes an autophosphorylation reaction during in vitro kinase assays (Fig. 3a, b) . A single radioactive band corresponding to the autophosphorylated Raf-1 enzyme is detected when this Raf preparation is subjected to in vitro kinase assays with 32 P-ATP; no other contaminating enzymes/substrates are detected in this preparation (even with long exposures of the gel). (3) Raf autophosphorylation is increased by the Raf activator Pak (Fig. 3b) , and (4) Raf activity (measured as either autophosphorylation or phosphorylation of MEK) is inhibited by GW5074 (Fig. 3a, b) . We then applied this information to studies of troponin phosphorylation. Figure 3c shows Raf and Pak phosphorylate different components of the troponin complex; Pak phosphorylates cTnI and Raf phosphorylates cTnT. Raf-dependent cTnT phosphorylation is increased by Pak, which activates Raf. Raf does not exert a reciprocal effect to influence Pak-dependent cTnI phosphorylation. Pak and Raf kinase activities are further resolved with GW5074, which abrogates Raf-dependent cTnT without blocking Pak-dependent cTnI phosphorylation. Of note, cTnI phosphorylation by Pak was consistently increased by GW5074 (in assays both with Pak alone and with Pak ? Raf). These results suggest that GW5074 might act as a direct Pak activator and deserves further study.
Troponin T phosphorylation sites have been mapped to Thr 197 , Ser 201 , Thr 206 , and Thr 287 . To determine whether Raf phosphorylate cTnT at Thr 206 (the functionally critical phosphorylation site) we used recombinant troponin complexes containing equimolar amounts of cTnI, cTnC, and cTnT (either WT or harboring T206E substitution). Figure 3c shows that cTnT-T206E is not a substrate for Raf, including in assays that contain Pak to increase Raf activity. These results indicate that Raf acts as a selective cTnT-Thr 206 kinase. Interestingly, Pak-dependent cTnI phosphorylation is decreased in assays with cTnT-T206E as substrate. While this finding was surprising, nonphosphorylatable TnT or TnI mutants that exert long-range effect to decrease the phosphorylation of the other subunit have been described in previous studies (Montgomery et al. 2001 (Montgomery et al. , 2002 . Finally, Fig. 3d shows that PKCd (a different serine/threonine kinase) phosphorylates WT-and T206E-substituted cTnT in a similar manner; PKCd also phosphorylates cTnI. These results validate the integrity of the cTnI-T206E protein and indicate that PKCd phosphorylates cTnT at sites other than Thr 206 .
Discussion
Raf proteins have recently emerged as key mediators of cellular growth, differentiation, and survival mechanisms, in the heart and other tissues. The focus of most studies has been on the role of Raf-1 to activate the ERK-MAPK pathway. Using molecular approaches involving overexpressing dominant-negative forms of Raf, Raf-1 has been implicated in endothelin-1-or phenylephrine-dependent cardiomyocyte growth, sarcomeric reorganization, and atrial natriuretic factor gene expression in cardiomyocytes (Harris et al. 2004 ) and Raf proteins have been implicated in ERK activation, ventricular hypertrophy, and survival in mice subjected to aortic banding. Studies in genetically modified mice suggest anti-apoptotic mechanisms for Raf-1 in the heart. Cardiac-specific disruption of the Raf-1 gene leads to increased cardiomyocytes apoptosis, left ventricular dilatation, and decreased systolic function at 10 weeks of age that is associated with an increase in ASK1, JNK, and p38 MAPK activities (without a detectable defect in agonist-dependent ERK activation; Harris et al. 2004) . Additional studies implicate ASK1 as a particularly important Raf-1 effector that contributes to in vivo cardiac remodeling, showing that the effect of Raf-1 knockout to induce apoptosis and cardiac dilatation and to decrease cardiac contractile function is prevented in the Raf1-ASK1 double knockout (Yamaguchi et al. 2004) .
Studies reported herein identify an additional role for Raf, as a cTnT-Thr 206 kinase. Since cTnT-Thr 206 phosphorylation has been implicated as a mechanism that attenuates force, actomyosin Mg-ATPase rate, Ca 2? sensitivity, and tension cost of mouse cardiac fiber bundles (Sumandea et al. 2003) , dynamic increases in cTnT-Thr 206 phosphorylation may be beneficial in instances of highenergy demand and protect the heart from over-stimulation. Finally, it is interesting to note that the Pak-Raf-Ask1 pathway may be uniquely poised to regulate contractility since Pak phosphorylates cTnI, Raf phosphorylates cTnTThr 206 and ASK1 phosphorylates cTnT (at T 197 ERKS 201 , in the vicinity of the KRQT 206 EREK sequence). Future studies that examine whether Raf-1-and ASK1-dependent cTnT phosphorylations are independently regulated or whether these phosphorylation reactions are controlled in an interdependent fashion will be important, as this would function to add further complexity to the process.
